Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity
about
Condensed Astatine: Monatomic and MetallicTumor immunotargeting using innovative radionuclidesAstatine Radiopharmaceuticals: Prospects and ProblemsSerum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.An overview of targeted alpha therapy.Radioimmunotherapy with α-particle-emitting radionuclides.Radioimmunotherapy with engineered antibodies.Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.Immunotherapy of malignant brain tumors.3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.Targeted alpha-therapy: past, present, future?Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211Radioimmunotherapy for high-grade glioma.Cancer therapy using radioimmunoconjugates. Implications for breast cancer.Cancer therapy with radiolabeled antibodies. An overview.Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysisReagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-clBifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies.
P2860
Q27450012-77EE318C-A2A9-4597-818E-DE36434CF8DAQ28083230-1DC348EB-5385-419D-A157-0281540FF409Q33640550-888FC81A-65B5-45AF-9254-43AA4F3ED44FQ33712484-64DA521D-74F2-44A9-85C6-D14A5ACF0B5BQ33925339-C42223BE-E391-49FB-AA5D-8DB0642C3033Q34238513-19B236BC-74D8-4289-919D-40087052022FQ34419562-F4409EAB-865A-474A-B9E8-FC09546F2927Q35681517-41CBB006-DEB2-4709-9EF1-0F019F676882Q36154918-F91035DC-1AD3-413D-94B9-89020FC44E80Q36162929-C857E24B-4431-4235-8324-7804E5AE3B62Q36422723-BF6BF25B-5B34-420D-A458-7D6A892501CAQ36691184-AD115C20-0E5F-4901-84CE-8BEA4B78B91AQ37085052-3C1B9FB7-EAD5-48F3-A340-2F0AFD7719BBQ37133715-76BFAACB-F7C7-499E-BE49-3B6AE4A4CE58Q38110937-9FC9DF49-33C8-48E6-86BD-5221E8C1DFE7Q40800326-4B4C42C0-2F29-416B-9995-D2AC3B0555C1Q40974532-FBA0507C-6890-4395-8945-0DED94406CA9Q41014982-CD4642CB-8F9F-48EE-B31D-42FAB6035D84Q41462504-1518B16D-D856-44A1-A1AF-5F915A1C7BC6Q41843217-19F89CE7-A8FA-4D9D-9059-967F7EA96220Q42074681-746D23FE-B7CD-4663-92D1-FFC7696CFD1DQ42573102-486CFD7B-D249-41C2-86EA-9CFA8FABA1A6Q47721286-8BB6DF80-5D28-4BBD-9348-23CB174DE2EA
P2860
Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity
description
1989 nî lūn-bûn
@nan
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Labeling monoclonal antibodies and F
@nl
Labeling monoclonal antibodies ...... nd in vivo localizing capacity
@ast
Labeling monoclonal antibodies ...... nd in vivo localizing capacity
@en
type
label
Labeling monoclonal antibodies and F
@nl
Labeling monoclonal antibodies ...... nd in vivo localizing capacity
@ast
Labeling monoclonal antibodies ...... nd in vivo localizing capacity
@en
prefLabel
Labeling monoclonal antibodies and F
@nl
Labeling monoclonal antibodies ...... nd in vivo localizing capacity
@ast
Labeling monoclonal antibodies ...... nd in vivo localizing capacity
@en
P2860
P356
P1476
Labeling monoclonal antibodies ...... nd in vivo localizing capacity
@en
P2093
M R Zalutsky
P2860
P304
P356
10.1073/PNAS.86.18.7149
P407
P577
1989-09-01T00:00:00Z